Philips has agreed to acquire SpectraWAVE, a Massachusetts-based medical device company focused on technologies to help diagnose and guide treatment for patients with coronary artery disease. SpectraWAVE’s technology specialises in advancing intravascular imaging and physiological assessment with AI. This acquisition positions Philips at the intersection of diagnostic imaging, cardiovascular health, and AI-driven healthcare. This acquisition will strengthen Philips’ presence in the intravascular imaging, p ...

Core Viewpoint - Royal Philips has announced the acquisition of SpectraWAVE, Inc., which specializes in Enhanced Vascular Imaging (EVI) and AI applications in medical imaging, aimed at improving treatment for coronary artery disease, a condition affecting over 300 million people globally [2][4][6]. Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation [15][16]. - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people [16]. Acquisition Details - The acquisition of SpectraWAVE will enhance Philips' portfolio in the coronary intervention segment, integrating AI-powered innovations in intravascular imaging and physiological assessment [4][7][9]. - Financial terms of the acquisition have not been disclosed [13]. Technology Integration - SpectraWAVE's HyperVue Imaging System combines DeepOCT and NIRS technologies to provide detailed imaging of coronary arteries during procedures, facilitating rapid setup and automated AI analysis [8][10]. - The X1-FFR technology from SpectraWAVE offers AI-enabled physiological assessments from a single angiogram, enhancing the workflow for percutaneous coronary interventions [11]. Market Impact - The integration of SpectraWAVE's technologies with Philips' Azurion platform is expected to significantly increase the adoption of advanced imaging and physiological assessment in treating coronary artery disease [9][12]. - Philips aims to expand clinician choice and improve patient outcomes through the convergence of intravascular imaging, coronary physiology, and AI [6][7].

Core Insights - Royal Philips has announced an agreement to acquire SpectraWAVE, Inc., which specializes in Enhanced Vascular Imaging (EVI) and AI applications in medical imaging, particularly for coronary artery disease [5][10][14] - The acquisition aims to enhance Philips' capabilities in image-guided therapy, particularly in the coronary intervention segment, by integrating SpectraWAVE's advanced technologies [7][10][14] Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation, with a strong emphasis on image-guided therapy [19] - SpectraWAVE, founded in 2017 and based in Bedford, Massachusetts, employs over 70 people and is recognized for its innovative intravascular imaging and physiological assessment technologies [5][19] Technology and Product Integration - The acquisition will incorporate SpectraWAVE's HyperVue Imaging System, which combines DeepOCT and NIRS technologies for detailed imaging of coronary arteries during procedures [11][14] - SpectraWAVE's X1-FFR technology provides AI-enabled physiological assessments from a single angiogram, enhancing the workflow for percutaneous coronary interventions [12][14] Market Impact - The integration of SpectraWAVE's technologies is expected to significantly increase the adoption of coronary intravascular imaging and physiological assessment, improving patient outcomes [10][14] - Philips' Azurion platform, which is already used to treat over 7.6 million patients annually in more than 80 countries, will benefit from the addition of SpectraWAVE's innovations [15][19]